Mental Health in Bladder Cancer Patients: Clinical Implications and Outcomes
Mental Health in Bladder Cancer Patients, impact of a bladder cancer diagnosis on risk of suicide, improving outcomes for patients with bladder cancer.
Mental Health in Bladder Cancer Patients, impact of a bladder cancer diagnosis on risk of suicide, improving outcomes for patients with bladder cancer.
Ashish Kamat introduces Jeffrey Holzbeierlein, who discusses the recent updates to the American Urological Association’s (AUA) guidelines for managing non-muscle invasive bladder cancer. Published in…
APCCC 2024, metastatic hormone-sensitive prostate cancer (mHSPC), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), ARCHES trial, enzalutamide, Delta-like ligand 3 (DLL3), LuPSMA.
Sam Chang and Siamak (Sia) Daneshmand discuss the ABLE-41 trial, focusing on the real-world usage of nadofaragene firadenovec for bladder cancer. Discussing the trial’s design…
APCCC 2024, Radioligand Therapy, Dosing of Radioligand Therapy, Dosing of Radioligand Therapy in Special Situations And/or Toxicity, 177Lu-PSMA, VISION trial, Lu-PSMA therapy, Lu-PSMA I&T, ENZA-p…
Zachary Klaassen and Stephen Williams delve into the economic and treatment implications of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Dr. Williams, with…
APCCC 2024, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), Radioligand Therapy, FDG PET, VISION trial, TheraP trial, 68Ga-PSMA-11, “VISION-TheraP” gap, 177Lu-SPECT/CT imaging, 18F-FDG PET/CT,…
Cora Sternberg discusses the significant advancement in the treatment of urothelial carcinoma, focusing on enfortumab vedotin (EV) in combination with pembrolizumab. This combination, recently approved…
Alicia Morgans and Alberto Bossi discuss the integration of local prostate treatment in metastatic hormone-sensitive prostate cancer, focusing on findings from the PEACE-1 trial and…
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
prostate cancer, BRCA-Deficient Metastatic Prostate Cancer, metastatic castration-resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA), DNA damage response (DDR), DDR Genes, BRCA2 in ctDNA, genomic…